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Abstract: It is generally accepted that acute myelogenous leukemia (AML) patients are immunocompromized. On the 
other hand, antileukemic immune reactivity is important for the improved survival of AML patients treated with alloge-
neic stem cell transplantation and antileukemic immunotherapy is also considered for patients treated with conventional 
chemotherapy. In this article, we review the available studies of disease- and therapy- induced immune dysfunctions in 
AML patients, including the function of the cellular innate and adaptive immune system of AML patients (i) with newly 
diagnosed disease before treatment, (ii) immunological functions of AML patients with severe therapy induced cytopenia 
before hematopoietic reconstitution; and (iii) the immune reconstitution following the initial period of hematopoietic re-
constitution after autologous and allogeneic stem cell transplantation. A more detailed knowledge about the immune sys-
tems of these patients is essential for an optimal design of future clinical immunotherapy studies in AML. 
Keywords: Acute myelogenous leukemia, Immune system, Chemotherapy. 
INTRODUCTION 
 Acute myelogenous leukemia (AML) is characterized by 
clonal proliferation of immature myeloid precursors and an 
arrest in the maturation of these cells [1]. This results in ac-
cumulation of a leukemic blast population in the bone mar-
row (BM) and eventually in the peripheral blood (PB). The 
bone marrow infiltration causes a decrease in the production 
of and thereby a reduction in the peripheral blood levels of 
mature myeloid cells; resulting in thrombocytopenia, anemia 
and granulocytopenia. 
 It is well known that AML patients are immunocom-
promized and have an increased risk of infections [1]. Fatal 
infections are an important cause of the treatment-related 
mortality especially in elderly individuals. AML patients 
often have neutropenia initially due to the disease and later 
eventually due to intensive chemotherapy. However, as will 
be seen from the studies reviewed below these patients can 
also have additional disease- or therapy-induced dysfunc-
tions of the cellular immune system. One would expect that 
these dysfunctions differ between patients due to for exam-
ple differences in AML cell phenotypes, chemotherapy 
regimen and age-dependent alterations of the immune sys-
tem. 
THE IMMUNE SYSTEM IN PATIENTS WITH UN-
TREATED AML 
Natural Killer Cells: The Importance of AML Cell Bur-
den, NCR
dull 
NK Cell Phenotype and NK-Inhibitory 
AML Cell Phenotype 
 Natural killer (NK) cells (Table 1) are a heterogeneous 
lymphoid population comprising 10–15% of all peripheral 
lymphocytes, and they seem to be involved in antitumor ac-
tivity as well as tumor surveillance [2, 3]. Elevated levels of 
lymphocytes with NK phenotype have been reported at the  
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time of diagnosis in AML [4]. CD56
+
, CD16
+
CD2
+
 and 
CD16
+
CD2
-
 NK cells were then found significantly in-
creased in peripheral blood, but only the CD56
+
 NK cells 
were additionally increased in bone marrow [4]. When these 
authors divided the AML cases into two groups according to 
the absolute number of circulating NK cells, the patients 
with the highest levels also showed an increased proportion 
of circulating leukemic blasts [4].  
 Despite the increased NK cell levels, several other stud-
ies report NK cell dysfunction [5-8] or impeded NK cell 
maturation [9] in patients with cancer, including preleukemic 
myelodysplastic syndromes (MDS) as well as leukemia. In 
accordance with this, it has been suggested that NK cells in 
leukemic patients display a more inhibitory AB haplotype 
killer cell immunoglobulin-like receptor (KIR) phenotype 
compared to healthy controls (Table 2, Fig. 1) [10]. Addi-
tionally, it is hypothesized that leukemic cells may have 
evolved an escape mechanism from immune surveillance 
based on the dominance of inhibitory KIR ligands over acti-
vating KIR ligands displayed on the leukemic cells (see Ta-
ble 3) [11].  
 Recently, deficient expression of the natural cytotoxicity 
receptors (NCR
dull
; NKp30, NKp44 and NKp46) in NK cells 
from AML patients was reported (Table 3) [5, 12]. This 
NCR
dull
 phenotype was possibly induced by direct contact 
with leukemia blasts and NK cells, and not via the cytokine 
network. Moreover, NCR
dull
 NK cell phenotype was associ-
ated with poor survival of AML patients [12]. The influences 
of the leukemic cells upon the NK lymphocytes still remain 
unclear. However, based on the above mentioned reports, it 
is justified to state that both qualitative as well as quantita-
tive disturbances in the NK cell system can be detected in 
AML patients (Table 2). 
Dendritic Cells: Immature Leukemic Dendritic Cells as a 
Cause of Immunosuppression? 
 Dendritic cells (DCs) (Table 1) are central in the presen-
tation of tumor antigens to the adaptive arms of the immune 
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Table 1. Some of the Circulating Cells of the Immune System 
 Cell type  Typically surface markers for  
distinguishing 
Typically associated cytokines  
Innate      
 NK cells Natural killer cells CD56 CD16 CD94 IFN, TNF-, IL10 [2] 
 mDCs Myeloid dendritic cells CD11c CD13 CD33 IFN type I [14] 
 pDCs Plasmacytoid dendritic cells CD123 CD62L CD36 IFN type I [14] 
Adaptive      
 T T lymphocytes CD3  [21] 
 TH1 Helper T cell type 1  CD4 IL12R12 IFN, IL2, TNF  
 TH2 Helper T cell type 2 CD4 IL12R1 IL4, IL5, IL6  
 TC1 Cytotoxic T cell type 1 CD8
 CD25 CCR5 IFN  
 TC2 Cytotoxic T cell type 2 CD8
 CD25 CCR4 IL4  
 Treg Regulatory T cell CD4
 CD25hi IL10, TGF [66] 
 NKT Natural killer T cells CD3 CD56 IFN, IL4 [48] 
 B B cells CD19+ IL12, TNF [3, 13] 
An overview of the immune cells comprising the cellular innate and adaptive immune system, however, there are heterogeneity within each subsets that are not shown in this table. 
 
Table 2. The Cellular Immune System in Untreated AML Patients 
Cell type Abnormality Ref. 
 Natural killer cells Increased CD56+, CD16+CD2+, and CD16+CD2- NK cell levels  
More inhibitory killer cell immunoglobulin-like receptors (KIRs) expressed 
Deficient expression of natural cytotoxicity receptors (NCRdull) 
NCRdull expression correlate with worse outcome 
[4] 
[10] 
[5, 12] 
[12] 
Dendritic cells Quantitative imbalance of mDCs versus pDCs 
Leukemic blasts can be misidentified as DCs 
[19] 
[17] 
T cells Close to normal CD4/CD8 ratio 
Normal absolute numbers of CD3+CD8+ and CD3+ CD8-  
Increased PB CD8+CD57+ T cells within the CD8+ cells 
Normal TH1 and TH2 cytokine profile 
Reduced T cell CD3- expression 
Functional within a microenvironment dominated by AML cells 
Decreased V24+ NKT cells correlated with worse prognosis 
Increased CD3+CD56+ NKT cells in PB 
Increased proportions of CD4+CD25HIGH Treg cells 
AML cells IDO expression correlates with increased numbers of Treg cells 
[46, 47] 
[46] 
[4] 
[46] 
[64] 
[47] 
[57] 
[4] 
[74] 
[75] 
A summary of the hereto characterization of the natural killer (NK) cells, dendritic cells (DCs) and T lymphocytes in untreated AML patients. PB: peripheral blood; IDO: In-
doleamine 2,3-dioxygenase; mDC: myeloid DC; pDC: plasmacytoid DC; NKT: natural killer T; Treg: regulatory T. 
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Fig. (1). The AML cell promoting immune dysfunctions. 
Some of the immune dysfunctions described in AML are; i) the natural killer (NK) cells seem to display a more inhibitory than activating 
receptor phenotype, ii) the AML cells display more inhibitory than activating NK cell ligands, iii) the AML cell microenvironment inhibit T 
cell receptor (TCR) signaling and thus T cell activation, iv) increased expression of indoleamine 2,3-dioxygenase (IDO) correlates with in-
creased numbers of regulatory T (Treg) cells, and v) AML cell resistance to perforin (P) and FasL (CD95L) mediated cell death. 
system, and they are important in maintaining homeostasis 
and peripheral tolerance [3, 13, 14]. There are several reports 
of DC defects in cancer patients (reviewed in [15]). Abnor-
mal frequencies as well as abnormal differentiation and/or 
maturation possibly caused by cancer derived soluble media-
tors, are among the dysfunctions described [15]. Immature 
DCs have been described to induce regulatory T cells induc-
ing T cell anergy [16], and because AML cells themselves 
may be classified as malignancy derived from DC precursors 
[17], one might hypothesize the leukemic cells to behave as 
immature DCs (Fig. 2). 
 A number of studies concerning AML throw light on the 
generation of leukemic DCs in the context of immunother-
apy (reviewed in [18]). There is to our knowledge only one 
study concerning the remaining non-leukemic DCs in AML; 
Mohty et al. [19] reported a quantitative imbalance in circu-
lating blood myeloid DCs (mDCs) and plasmacytoid mono-
cytes (pDCs) in 70% of the AML patients examined (Table 
2). However, both subsets included leukemic cytogenetic 
features [19], and as pointed out recently by Panoskaltsis 
[17], the non-leukemic DC subset identification can be diffi-
cult because leukemic blasts may be misidentified as normal 
DCs due to the presence of DC-associated markers. Thus, 
these observations have to be interpreted with great care.  
 In patients with breast cancer the presence of pDCs 
(CD123
+
 BDCA2
+
), revealed by immunohistochemistry of 
the breast cancer tissue, suggested a disease-promoting activ-
ity of pDCs that was possibly caused by pDCs strong pro-
duction of type I IFN [20]. It is not known whether similar 
mechanisms are operative in AML, but at least for T cells the 
release of hematopoietic growth factors may support disease 
progression (see below). 
T Lymphocytes: Normal Levels and Functional Status 
 T lymphocytes are a heterogeneous population compris-
ing cell subsets like cytokine-secreting CD4
+
 T helper (TH1 
or TH2) cells, cytotoxic killer CD8
+
 T (TC1 or 
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Table 3. Human NK Cells Surface Receptors, their Ligands 
and Signaling Type 
NK cells inhibitory receptors
3 
Receptor family Receptor
1 
Known ligands
2 
KIR+ KIR2DL1 (CD158a)+ HLA-C group 2 
KIR+ KIR2DL2/3 
(CD158b)+ 
HLA-C group 1 
KIR KIR3DL1 HLA-B alleles 
KIR KIR3DL2 HLA-A alleles 
LIR LIR-1/IL T2 (CD85j) HLA class I 
NKG2 NKG2A 
(CD94/CD159a) 
HLA-E 
KLR KLRG1 E/N/P-cadherin 
NKR NKR-P1 (CD161) LLT1 
IGSF Siglec-7 (CD328) Sialic acid 
IGSF Siglec-9 (CD329) Sialic acid 
IGSF IRp60 (CD300a) Unknown 
NK cells activating receptors
4 
Receptor family Receptor
1 
Known ligands
2 
KIR KIR2DS HLA class I 
KIR KIR3DS HLA class I 
NKG2 NKG2C/E (CD94) HLA-E 
NKG2* NKG2D* MICA/B*, ULBP* 
NCR* NKp30* Unknown* 
NCR* NKp44/46* Influenza HA 
FcR CD16 IgG Fc region 
IGSF 2B4 (CD244) CD48 
TNF-R CD27 CD70 
CD28 CD28 CD80, CD86 
CD2 CD2 LFA-3 (CD58) 
After engagement of the NK cell receptor1 by the specific ligand2, the receptor exerts 
an inhibitory3 or activating4 signal to NK-mediated lysis of target cell [166, 167]. + NK 
cell receptors upregulated in AML patients [10]. * Downregulated NK cell receptors 
and ligands in AML patients [12, 105]. KIR: Killer Cell Ig-Like Receptor; LIR: leuko-
cyte Ig-like receptor; KLR: killer cell lectin-like receptor; IGSF: immunoglobulin 
superfamily; FcR: Fc gamma receptor; TNF-R: tumor necrosis factor receptor; NCR: 
natural cytotoxicity receptor.  
TC2), natural killer T (NKT) cells and regulatory T (Treg) 
cells (Table 1) [3, 13, 21]. Altered ratios of TH1 versus TH2 or 
TC1 versus TC2 cells are observed in several malignancies 
[22-31]. However, a decreased total T cell number without 
such shifts is also reported in cancer patients [32, 33], as 
well as close to normal or increased T cell numbers [34, 35]. 
The most probable explanation for this variation is that there 
are differences between malignancies and possibly also be-
tween individual cancer patients. Age and race-dependent 
differences may also contribute. Furthermore, an abnormal 
CD4:CD8 ratio has been reported in certain malignancies 
[36-40]. This ratio can vary depending on the immunological 
compartment investigated: lymph node versus peripheral 
blood versus tumor-infiltrating lymphocytes [38, 40, 41]. 
Additionally, it is suggested that cancer patients have more 
memory and less naive T cells applicable among PBL or 
tumor infiltrating lymphocytes [42-45].  
 Only few reports regard the T lymphocyte subsets in pa-
tients with de novo AML. Vidriales and colleagues [4] re-
ported normal frequencies of CD4
+
CD45RA
+
 and 
CD4
+
CD29
+
 cells in the PB but increased numbers of the 
cytotoxic CD8
+
CD57
+
 subset among CD8
+
 cells [4]. A more 
recent report [46] outlined that the absolute numbers of 
CD3
+
CD8
+
 and CD3
+
CD8
-
 (putative CD4
+
) T cells in whole 
blood of 13 patients with AML were similar to those of 
healthy controls. However, there was a tendency for higher 
numbers of CD8
+
 T cells in the patients and this was also 
reflected in lower CD4:CD8 ratios [46]. The close to normal 
CD4:CD8 ratios were also observed in our own recent stud-
ies [47]. Thus, no major quantitative T cell defects have been 
described for patients with newly diagnosed AML. 
 Panoskaltsis et al. [46] measured the intracellular cyto-
kine levels of circulating lymphocytes derived from AML 
patients. They did not find any significant changes in the IL-
4, IL-10, IL-12 or IFN levels for the cell subsets derived 
from patients compared with healthy individuals, suggesting 
normal TH1 and TH2 profiles. However, a nonsignificant trend 
towards higher absolute numbers and percentages of CD8
+
 
and CD8
- 
lymphocytes with detectable IL-10, IL-12 and 
IFN was observed for the AML patients. 
 To further investigate whether T cells were qualitatively 
affected in AML patients, functional analysis of T lympho-
cytes after in vitro activation through the CD3/TCR complex 
and CD28 costimulatory molecule, within a microenviron-
ment dominated by autologous AML blast population, was 
recently reported [47]. When these results were compared 
with samples from healthy controls on a per cell basis the 
IFN production for the anti-CD3 plus anti-CD28 activated 
AML samples was not significantly different from the 
healthy controls, suggesting that at least IFN responsiveness 
of T cells was not modified in the presence of the AML cells 
[47]. Thus, this last study did not detect any functional T cell 
defect either, supporting the findings of Panoskaltsis et al. 
[46].  
 NKT cells are a heterogeneous group of T lymphocytes 
expressing NK cell-associated receptors and  T cell-
receptor (TCR) that are lipid or glycolipid antigen-CD1d 
restricted rather than antigen-MHC restricted [48]. In cancer 
patients NKT cells may be both reduced and increased in 
numbers and may also have impaired ability to release cyto-
kines [49-52]. Additionally, NKT cell number and function 
has been linked to prognosis in some malignancies [53-56]. 
This may also be true in AML as circulating V24+ NKT 
cells are decreased in patients with progressive disease [57]. 
In contrast, increased CD3
+
CD56
+
 NKT cells have been 
found in PB from AML patients, while normal levels were 
found in BM [4]. Thus disease-induced alterations may dif-
fer between NKT cell subsets.  
 Misoguchi et al. [58] were the first to suggest that im-
mune dysfunction in cancer patients was due to an altered 
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composition of the T-cell receptor signaling complex. To-
day, decreased expression of CD3-  (CD3- zeta) in T cells 
has been demonstrated in several malignancies [59-62]. Re-
duced CD3- expression in tumor infiltrating lymphocytes 
even seems to be an independent prognostic factor for pa-
tients with oral carcinoma [63]. Buggins et al. [64] reported 
abnormal expression of CD3- in 64 % out of 46 myeloid 
leukemia patients examined (of which 11 were AML) and 
successful remission induction was associated with recovery 
of CD3- expression. Also, the CD3- associated protein 
tyrosine kinases (p56
lck
, p59
fyn
, and ZAP-70) showed vari-
able but often reduced expression in these patients [64]. Ad-
ditionally, in a murine AML model [65] there were observed 
reduced responses (proliferation and IL-2 secretion) to mito-
genic anti-CD3- but not to PMA/ionomycin (which is TCR 
independent) as early as one week following the injection of 
leukemic cells, whereas loss of CD3- protein expression 
together with intracellular signaling abnormalities (i.e. cal-
cium mobilization and tyrosine kinase activity) were de-
tected only in advanced disease (4 weeks after injection). It 
was also shown in vitro that leukemia-derived factor(s) 
stimulated splenic macrophages to secrete a second soluble 
factor(s) that caused the loss of CD3- [65]. The AML-
associated T cell abnormalities are summarized in Table 2.  
 From the above mentioned studies it is difficult to reach a 
firm conclusion, partly due to the question of patient hetero-
geneity and the low number of patients in some of these 
studies. However, it is justified to conclude that there are no 
major quantitative defects for the total T cell population and 
most of the examined T cell subsets in untreated AML, but 
NKT cells may be an exception. Another exception is the 
increased frequency of Treg cells (see below). The altered 
expression of the TCR signaling complex is probably the 
best example of a functional disturbance of T cells in AML 
(Fig. 1). 
 
Treg Cells: High Levels may Play a Critical Role in AML-
Associated Immunosuppression  
 Treg cells (Table 1) control autoimmune T cell reactivity 
in the periphery and may also suppress immune responses 
against cancer cells (reviewed in [66]). An increased number 
of Treg cells has been reported for patients with ovarian can-
cer, lung cancer, breast cancer, gastrointestinal malignancies 
and lymphoma [67-73]. In concordance with these findings, 
Wang et al. reported significantly higher proportions of 
CD4
+
CD25
high
 Treg cells for PB and BM in AML patients 
compared with healthy controls [74]. These CD4
+
CD25
high
 
cells were (i) CD45-RA
-
, CD69
-
, CD45-RO
+
, CD95
+
, inter-
cellular CTLA-4
+ 
; (ii) secreted low levels of TNF- and IL-
10 and did not release IL-2, IL-4, IL-5 or IFN; and (iii) be-
haved as Treg cells by inhibiting CD4
+
CD25
-
 T cell prolifera-
tion and cytokine production during in vitro activation [74]. 
The AML cell expression of a key enzyme in the tryptophan 
metabolism; Indoleamine 2,3-dioxygenase (IDO), has been 
correlated with increased levels of circulating 
CD4
+
CD25
+
FOXP3
+
 Treg cells in patients with AML at diag-
nosis [75]. Subsequent in vitro experiments indicated that 
AML cells induce T-cell anergy by directly converting 
CD4
+
CD25
-
 T cells into CD4
+
CD25
+
 Treg cells through an 
IDO-dependent mechanism [75]. Thus, CD4
+
CD25
+
 Treg 
cells are increased and possibly play a critical role in immu-
nosuppression in AML (Fig. 1).  
LEUKEMIA ASSOCIATED ANTIGENS: A POSSIBLE 
ROLE IN DIAGNOSTIC CLASSIFICATION, PROG-
NOSTIC EVALUATION OR IMMUNOTHERAPEU-
TIC TARGETING? 
 Several mutated or overexpressed proteins seem to be 
processed and presented to the immune system as tumor an-
tigens leading to cellular and/or humoral responses [76]. One 
of the most extensively studied cancer-associated antigens is 
p53 [77], but more recent studies have demonstrated that  
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Are AML cells behaving like immature DCs inducing T cell anergy? 
Normally the immature dendritic cells (DCs) take up antigens, process the antigens while mature and finally induce T cell activation. How-
ever, immature DCs have been described to promote regulatory T cells inducing T cell anergy. Because AML cells themselves may be classi-
fied as malignancy derived from DC precursors one might hypothesize the leukemic cells to behave as immature DCs. 
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autoantibodies against a wide range of autoantigens can be 
detected in patients with malignant disorders [76, 78]. Zhang 
et al. investigated a group of 174 cancer patients for autoan-
tibodies against 7 known antigens, each autoantibody could 
then be detected in 10-20% of the patients and approxi-
mately half of the patients had at least one autoantibody [76]. 
Cancer-associated humoral autoimmunity thus seems to be a 
common phenomenon, but autoimmune disease is uncom-
mon in these patients [79].  
 The number of autoantibodies known to occur in AML 
patients is few compared to other malignancies. However, 
humoral responses against the following antigens have been 
detected at an increased frequency in AML patients com-
pared with healthy controls (Table 4): Wilms tumor gene 
product (WT1) [80, 81], single-stranded DNA (ssDNA) [82], 
anticardiolipin antibodies (ACA) [83], the M-phase phos-
phoprotein 11 (MPP11) [84], receptor for hyaluronan acid-
mediated motility (RHAMM) [85], myc associated zinc fin-
ger (MAZ) [86], per ARNT SIM (PAS) domain containing 1 
(PASD1) [87], cyclin B1 [88] and Rhamm-like protein [89]. 
Some of these autoantibodies have originally been detected 
in either disorders associated with tissue destruction such as 
systemic lupus erythematosus (SLE) (ssDNA) [82] or seri-
ous infections (ACA) [83], but tissue destruction alone (e.g. 
chemotherapy-induced cell damage) does not seem to be 
sufficient for development of humoral immune responses in 
AML [90].  
 Spontaneous T cell reactivity to leukemia associated an-
tigens (LAAs) in AML patients with newly diagnosed dis-
ease include WT-1 peptides, proteinase3 peptides [91], 
RHAMM (CD168) peptides [92], and Bcl-2 peptides [93], 
all verified by ELISPOT and at least one additional method 
(e.g. tetramer staining) (Table 4). Vaccination with LAA 
peptides is therefore tried in the treatment of AML [94]. 
 It is too early to conclude about the possible clinical im-
portance of antileukemic immune reactivity in patients with 
untreated AML. Future studies should probably focus on 
antibody/T cell signatures as possible prognostic signatures, 
the effect of anticancer therapy on this reactivity and the 
development of clinical procedures to enhance this anti-
leukemic reactivity.  
THE CYTOKINE NETWORK: IMMUNOREGULA-
TORY FACTORS ARE CONSTITUTIVELY RE-
LEASED BY PRIMARY HUMAN AML CELLS  
 Numerous immunosuppressive factors like TGF-, IL-10, 
vascular endothelial growth factor (VEGF), Fas-L and Fas 
have been detected in tumor microenvironments [95, 96]. 
Such tumor-derived factors can for instance induce apoptosis 
in T cells [96-99] or inhibit a Th1 response [100] and 
thereby contribute to local immunosuppression. Similar 
mechanisms seem to be operative in AML (Table 5). In addi-
tion to the above mentioned IDO-dependent Treg cell induc-
tion [75], the AML microenvironment seems to be immuno-
suppressive by inhibiting T cell cytotoxic activity [101, 102]. 
AML culture supernatants have in addition shown a TGF-, 
IL-10 and VEGF independent inhibition of T cell activation, 
T cell proliferation and Th1 cytokine production [102].  
 Chemokine release by primary AML cells appears in 
clusters, and the following three clusters could be identified 
based on correlations between chemokine levels: (i) CCL2-
4/CXCL1/8, (ii) CCL5/CXCL9-10, and (iii) 
CCL13/17/22/24/CXCL5 [103]. Several of these chemokines 
(e.g. CCL5, CCL17, CXCL10) are T cell chemotactic 
chemokines [104]. It seems most likely that the final func-
tional effect of this local chemokine release is recruitment 
and thereby enhancement of antitumor reactivity.  
 AML cell supernatants have been shown in experimental 
models to affect major signaling pathways involved in T cell 
activation and proliferation (summarized in Table 5); i) re-
duced nuclear translocation of the transcription factors 
NFATc and NF-B; ii) delayed activation of the mitogen-
activated protein (MAP) kinase c-Jun N-terminal kinase 1/2 
(JNK-1/2); iii) no phosphorylation of the cell cycle related 
proteins retinoblastoma protein (pRb), cyclin-dependent 
kinase-6/4 (CDK-6/4) cyclin D and Rb family member p130; 
and iv) no induction of the transcription factor c-Myc, the 
cell cycle protein cyclin D3 and the Rb family member p107. 
Calcium mobilization, the MAP kinase extracellular signal-
regulated kinase-1/2 (ERK-1/2) and p38, as well as the 
signal transducer and activator of transcription protein-5 
(STAT-5) remained unaffected [102]. Taken together these 
observations clearly demonstrate that AML-derived soluble 
mediators have extensive effects on the intracellular T cell 
signalling (Fig. 1). 
AML CELLS: IMMUNOLOGICAL ESCAPE PHENO-
TYPE AND RESISTANCE TO IMMUNOLOGICAL 
MEDIATED CELL DEATH 
 In addition to proposed immunosuppressive factors con-
stitutively released by AML cells, an immune escape pheno-
type of AML cells has been suggested (see Table 5). We 
have already mentioned the NCR
dull
 NK lymphocyte pheno-
type that is most possibly induced by direct contact with the 
leukemic blasts [12] and the high expression of inhibitory 
over activating KIR ligands on the AML cells [11] (Fig. 1). 
Moreover, ligands for NK cell-activating receptors are ex-
pressed only at very low levels in leukemic cells in 80 per-
cent of patients [105]. In vitro administration of differentia-
tion-promoting drugs upregulate NK cell-activating receptor 
expression and enhances the susceptibility of AML cells to 
Table 4. Leukemia Associated Antigens in Untreated AML Patients 
 Leukemia associated antigens Ref. 
Humoral recognized WT-1, MPP-11, PASD1, RHAMM, MAZ, cyclin-B1, Rhamm-like protein [81, 84, 85, 87-89] 
TC cell  recognized WT-1, proteinase3,  RHAMM, Bcl-2 [91-93] 
A brief summary of some of the antibody/B cells (humoral) and spontaneous cytotoxic T (TC) cell recognized leukemia associated antigens (LAAs) described in AML patients. WT-
1: Wilms tumor gene product-1; MPP-11: the M-phase phosphoprotein 11; PASD-1: per ARNT SIM (PAS) domain containing 1; RHAMM: receptor for hyaluronan acid-mediated 
motility; MAZ: myc associated zinc finger; Bcl-2: B-cell CLL/lymphoma 2. 
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NK cell-mediated lysis [105, 106]. Thus, the NK cell-escape 
phenotype alsocan be overcome, but differentiation-
promoting drugs may also prevent NK cytotoxicity by down-
regulation of NK cell activating receptors [107]. 
 The two major mechanisms by which immune effector 
cells exert their cellular cytotoxicity is through granule exo-
cytosis and Fas (CD95) ligation [108]. Granzymes and per-
forin are the major components of the cytotoxic granules in 
both T and NK cells [108]. A perforin- and Fas-mediated 
cell death resistance has been suggested for AML cells [96, 
109, 110] (Fig. 1), but due to the small numbers of patients 
included in these studies no firm conclusion can be made 
regarding the clinical significance. 
 The expression of the major histocompatibility complex 
(MHC) genome area class I and II is crucial for LAA presen-
tation. HLA class I molecules are reduced in AML blasts 
compared to normal monocytes [111]. Myeloid progenitor 
cells seem to temporarily express HLA class II molecules 
during differentiation to granulocytes and macrophages 
[112]. Primary human AML cells also express HLA class II 
molecules [113, 114]. A recent study outlines the importance 
of class-II associated invariant chain peptide (CLIP) expres-
sion and the HLA-DO:HLA-DM ratio for prediction of clini-
cal outcome of AML patients [114]. Based on these findings 
the authors suggested that HLA-DR
+
/CLIP
-
 AML cells were 
able to present leukemia-specific antigens and therby initiat-
ing an effective and long-lasting antitumor response, 
whereas this was not the case for HLA-DR
+
/CLIP
+
 AML 
cells [114].  
 Recently a study investigating the costimulatory expres-
sion profile of primary human AML cells concluded that i) 
the expression of costimulatory molecules in AML was very 
variable, ii) CD56
+
 AML subtypes were associated with an 
adverse prognosis, and iii) high expression of certain 
costimulatory molecules (e.g. CD80, CD86) also correlated 
with worse prognosis [115]. The negative effect of high 
CD86 (B7-2) expression has also been reported previously 
[116], whereas the results for CD80 (B7-1) expression are 
conflicting [111, 113, 115-117]. The association of adverse 
prognosis with high expression of certain costimulatory 
molecules, is contradictory to the hypothesis that high levels 
of costimulatory molecules are favorable for immunological 
recognition and destruction of AML cells and therefore 
would be expected to be associated with a good prognosis.  
 The costimulatory cytotoxic T-lymphocyte-associated 
antigen-4 (CTLA-4) is a negative regulator of T cell activa-
tion. Recently, CTLA-4 was reported constitutively ex-
pressed by 80% of AML samples tested [118, 119]. Blocking 
either PD-1L, CD80 or CTLA-4 in vivo prolonged the sur-
vival of naive mice engrafted with AML cells [120].  
 To conclude, additional studies are clearly needed to fur-
ther elucidate the role of the T cell costimulatory or inhibi-
tory molecules in AML to clarify whether these molecules 
have effects in immunoregulation, or whether high expres-
sion of these molecules is only a part of a functional AML 
cell phenotype associated with chemoresistance or a more 
aggressive disease. 
INTENSIVE AML CHEMOTHERAPY: EARLY IM-
MUNOLOGICAL RECONSTITUTION IS A GOOD 
PROGNOSTIC FACTOR 
Immune Function in AML Patients with Severe Chemo-
therapy-Induced Cytopenia  
 Cytotoxic antineoplastic therapy disrupts T cell homeo-
stasis and is the primary contributor to the severe clinical 
immunodeficiency observed in AML patients [121]. The 
Table 5. AML Induced Suppression of Immune Cells 
Mechanism Observations Ref. 
Soluble mediators Reduce T cell CD3- expression. 
Inhibit T cell activation, proliferation, TH1 cytokine production, and cytotoxic activity 
Inhibit major signaling pathways involved in T cell activation and proliferation; 
• Transcription factors (NFATc, NF-B, c-Myc) 
• Map kinase (JNK-1/2) 
• Rb family members (pRb, p130, p107) 
• Cell cycle related proteins (CDK-6/4, cyclin D3) 
Chemokine release clusters have been identified 
• CCL2-4/CXCL1/8 
• CCL5/CXCL9-10 
• CCL13/17/22/24/CXCL5 
[64] 
[102] 
[102] 
 
 
 
 
[103] 
Direct cell-cell contact Deficiently expression of activating ligands for NK cell-activating receptors  
High IDO expression correlate with high numbers of Treg cells 
Perforin- and Fas-mediated cell death resistance 
Reduced expression of HLA class I molecules 
MHC class II HLA-DR+/CLIP+ AML cells associates with adverse prognosis 
High expression of costimulatory molecules associates with adverse prognosis 
[11, 105] 
[75] 
[109] 
[111] 
[114] 
[115] 
IDO: Indoleamine 2,3-dioxygenase, CLIP: class-II associated invariant chain peptide. 
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impact of the immune system for outcome after chemother-
apy was recently elucidated by Behl et al. [122], finding that 
rapid absolute lymphocyte count recovery after induction 
chemotherapy predicts superior survival in AML.  
 In general, patients receiving chemotherapy for various 
malignant disorders seem to develop a CD4
+
 T lymphopenia 
together with high serum levels of the pleiotropic cytokine 
IL-7 [123, 124]. In contrast, AML patients with severe che-
motherapy-induced leukopenia and CD4
+
 T lymphopenia, 
showed decreased IL-7 serum levels, and the detection of 
circulating IL-7-responsive T cells in these patients indicated 
that variations in systemic IL-7 levels are functionally im-
portant and may contribute to the T cell defect in lym-
phopenic AML patients [125]. Other studies have demon-
strated that administration of recombinant IL-7 to humans 
could selectively increase total CD4
+
 and CD8
+
 T lympho-
cytes and decrease the percentage of CD4
+
 Treg cells [126]. 
The possible clinical use of IL-7 therapy in AML has not 
been investigated. 
 For AML patients with chemotherapy-induced cytopenia 
most circulating leukocytes are T lymphocytes, whereas B 
lymphocytes and monocytes show a wide variation among 
patients but usually represent less than 10% of the leuko-
cytes (Table 6) [127]. Most of the circulating T cells in can-
cer patients with chemotherapy-induced cytopenia seem to 
express the activation markers HLA-DR as well as CD25 
and CD69, and this is also true in human AML [128, 129]. 
Following chemotherapy there seems to be an absence of 
CD4
+
CD45RA
+
 T cells, all the remaining CD4
+
 T cells ex-
pressing the CD45RO
+
 isoform [121, 128]. 
 There have also been some reports regarding qualita-
tive/functional evaluation of T cells, these include the ex-
amination of cytokine release and cytokine responsiveness of 
in vitro expanded clonogenic T cells derived from AML pa-
tients with therapy-induced cytopenia [129-133]. These 
clonogenic cells constitute a minor population of circulating 
T cells including CD4
+
 and CD8
+
 TCR+ cells [130], and 
the cells secrete a wide range of immunoregulatory cytokines 
[131]. The frequency of these clonogenic T cells is often 
reduced compared to healthy individuals [130].  
 Very few studies have included functional analysis of 
circulating T cells other than the clonogenic minority. How-
ever, there are studies of the proliferative responsivness of T 
cell derived from AML patients with severe leucopenia 
evaluated in a whole blood assay [127, 134]. In this assay 
activated T cells were found to have proliferative respon-
siveness equal to healthy controls in the presence of optimal 
stimulation with anti-CD3 plus anti-CD28, but responses 
were significantly reduced in the patient samples when using 
anti-CD3 stimulation only. Furthermore, the responses were 
significantly lower for ALL than for the AML patients [127].  
 More recently, we reported that the in vitro activated T 
cells in this whole blood assay show a broad cytokine release 
profile including high and significantly correlated release of 
IFN and GM-CSF [135]. The anti-CD3 plus anti-CD28-
stimulated IFN release, but not GM-CSF release, was sig-
nificantly lower for AML patients than for healthy individu-
als. This difference is probably caused by combined qualita-
tive and quantitative defects within the remaining T cell 
population in the AML patients [127, 134]. Additionally, 
higher IFN and GM-CSF levels were significantly associ-
ated with older age, an observation clearly demonstrating 
that age therapeutic-dependent alterations have to be consid-
ered when clinical trials of immunotherapy are designed 
[135]. Significantly higher T cell proliferation and cytokine 
release were also observed when the novel drug PEP005 (a 
protein kinase C agonist) was added, thus indicating that 
pharmacological immunotargeting could be possible in these 
severely compromised patients [135]. 
Immune Reconstitution after Conventional Intensive 
Chemotherapy: the Impact of Thymic Atrophy  
 Effective immunological functions after chemotherapy 
and myeloablative therapy depend upon reconstitution of 
antigen specific T cells. For the recovery of T cells renewed 
thymopoiesis is crucial [136]. Thymus involution rapidly 
reduces its function to <5% of its maximal capacity after 
puberty [137, 138]. Therefore, when T cell levels are se-
verely decreased after chemotherapy, the ability to regener-
ate the T cell repertoire is severely compromised and wors-
ening occurs with increasing age [139]. Thus, the T cell re-
Table 6. Immune System in AML Patients with Chemotherapy-Induced Cytopenia 
Cell type Abnormality Ref. 
NK cells No studies  
DCs No studies  
T cells Circulating IL-7 responsive T cells 
Most T cells express CD45RO, HLA-DR, CD25, CD69 
Reduced frequencies of clonogenic T cells 
In vitro aCD3+aCD28 T cell proliferative response equal to healthy control 
In vitro aCD3+aCD28 T cell IFN secreting response lower than healthy controls 
T cell directed pharmacological targeting may be possible  
[125] 
[127] 
[130] 
[127] 
[135] 
[135] 
B cells Generally less than 10% of the leukocytes [127] 
NK: natural killer cells; DCs: dendritic cells; aCD3: antibody against CD3; aCD28: antibody against CD28. 
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generation can be divided into two different pathways 
mainly dependent upon age. Firstly, in young patients HSCs 
generate T cell committed HPCs (T-HPCs: CD34
+
CD7
+
CD3
-
) in the BM that transmigrate to the thymus where the T-
HPCs down-regulate the CD34 antigen, up-regulate the ex-
pression of T cell receptors (TCRs) and CD3 antigen and 
finally differentiate into naive CD4
+
 and CD8
+
 T cells [140, 
141]. Alternatively, adult patients with thymic atrophy re-
generate the T cell compartment principally by antigen in-
duced conversion of naive to memory T cells and subsequent 
expansion [141-143]. This implies that adults show a delay 
in peripheral T cell regeneration as well as increased inci-
dence of opportunistic infections compared to younger indi-
viduals [144]. Among suggested approaches to treat such 
immunodeficiency states in adults are the use of sex-steroid 
ablation or androgen blockade to activate thymic regenera-
tion which may lead to the reversal of age-related thymic 
atrophy [145-147]. However, fatal infections are uncommon 
after hematopoietic reconstitution, and only low- or nontoxic 
strategies to enhance immune reconstitution are therefore 
justified. 
 Effective immunological function after chemotherapy 
also depends upon reconstitution of antigen specific antibody 
production by B lymphocytes as well as NK cell reconstitu-
tion. In contrast to T cells, B cells and NK cells differentiate 
essentially in the bone marrow and thus depend upon an in-
tact BM microenvironment. Additionally tissue-specific NK 
cell development (e.g. thymus) is hypothesized to exist 
[148], and thus thymic atrophy and age might also affect NK 
cell restoration.  
Complete Haematological Remission and Recovery of the 
Immunesystem 
 Very few studies have examined the T cell system in 
AML patients after hematopoietic reconstitution. Long-
lasting T cell defects can occur after intensive chemotherapy 
for other malignancies, especially in adult patients [121]. 
One would expect similar defects to occur after AML ther-
apy. However, as mentioned above, the abnormal CD3- 
expression on T cells from AML patients was recovered 
when achieving remission [64]. Furthermore, low expression 
of the activating natural cytotoxicity receptors (NCR
dull
) on 
NK cells (see above) in AML patients was completely or 
partially restored in patients achieving remission [12]. These 
studies suggest that the continued presence of leukemia cells 
are necessary for abnormal CD3- expression on T cells and 
NCR down-regulation on NK cell. 
IMMUNE RECONSTITUTION AFTER AUTOLO-
GOUS STEM CELL TRANSPLANTATION: INFLU-
ENCED BY STEM CELL MOBILIZATION RE-
GIMES? 
 Similar to the significance of the immune system recon-
stitution after induction therapy [122], early lymphocyte re-
covery is a predictive factor for prolonged survival after 
autologous stem cell transplantation (auto-SCT) for AML 
patients [149].  
 The recirculation pattern of injected leukocyte subpopu-
lations during the first 24 hours after auto-SCT of AML dif-
fers between leukocyte subsets [150]; i) the number of CD3
+
 
T lymphocytes increases during this period, ii) CD56
+
 NK 
cells decrease rapidly after auto-SCT and remain low 
throughout the observation period of 24 hours, and iii) B 
lymphocyte levels are also low during the first 24 hours 
[150]. 
 The early reconstitution of the T lymphocyte system after 
both auto- and allo-SCT is mainly due to the peripheral ex-
pansion of mature T cells transferred with the graft [142, 
151]. The recovery of polyclonal T lymphocytes occurs 
gradually, and complete reconstitution of humoral and cellu-
lar immunity may take more than one year [152]. Similar to 
the observations in patients only receiving intensive chemo-
therapy, there seems to be an absence of CD4
+
CD45RA
+
 T 
cells early after auto-transplantation with a remaining popu-
lation of CD4
+
CD45RO
+
 circulating T lymphocytes [121, 
128, 153]. One study has suggested that BM-resident mem-
ory T cells are resistant to both pretransplant chemotherapy 
and ex vivo pharmacological purging and thus may contrib-
ute to the immune reconstitution after auto-SCT [154]. 
 G-CSF is the growth factor most commonly used for 
stem cell mobilization. T cells in PB after HSC mobilization 
with G-CSF have been analyzed: some studies indicate that 
G-CSF doubles the total number of circulating T cell without 
major changes in the fractions of various T cell subsets [141, 
155]. However, other functional studies [156-158] indicate 
that G-CSF might affect the cytotoxic T cells by stimulating 
these lymphocytes to preferentially release type 2 cytokines 
(IL-4 and IL-10) rather than type I (IFN, TNF-, IL-2) upon 
activation. G-CSF may in addition increase the number of 
circulating Treg cells [159]. 
THE EARLY IMMUNE RECOVERY AFTER ALLO-
GENEIC STEM CELL TRANSPLANTATION IS IM-
PORTANT FOR SUCCESSFUL TRANSPLANT OUT-
COME 
 Allogeneic stem cell transplantation (allo-SCT) can be a 
curative treatment for younger AML patients. Bone marrow 
(BM), cord blood (CB), and G-CSF-mobilized peripheral 
blood progenitor cell (PBPCs) can be used. A comparison of 
the cellular composition of leukapheresis products (LPs), CB 
allografts and BM allografts demonstrated that the composi-
tion of the graft lymphocytes differed considerably. T, B and 
NK cells were highest in LPs and lowest in CB allografts 
[141]. Also, early immune recovery is possibly enhanced 
following blood stem cell allografting compared with BM 
allografting; this is probably due to the large number of ma-
ture lymphocytes in blood stem cell allografts [160]. 
 Recently, lymphocyte recovery at 3, 6 and 12 months 
after allo-SCT, was characterized for patients with various 
hematological malignancies, including AML [161]. In sum-
mary, this study revealed: i) a rapid CD56
+
 NK cell recovery 
at 3 months, ii) the CD19
+
 B cell recovery was slow as only 
45% of patients recovered CD19
+
 cell counts above 
50x10
6
/L at 3 months, iii) an inverted CD4:CD8 ratio was 
observed during the first year, iv) the CD4
+
 helper T cell 
reconstitution at 3 months was associated with improved 
overall survival when using the cutoff value of 200x10
6
/L 
CD4
+
 helper T cells, v) rapid CD4
+
 helper T cell recovery 
was also associated with a higher CD4
+
 helper T cell trans-
plant dose and HLA-matched sibling donors, vi) an early 
CD4
+
 helper T cell recovery at 3 months correlated with a 
subsequent faster helper T cell recovery until 12 months but 
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not with faster B cell recovery, and vii) rapid recovery of 
CD4
+
 helper T cells at 3 months was a favorable prognostic 
factor in terms of overall survival and non-relapse mortality 
[161]. In addition to the non-relapse mortality reduction the 
donor T cells are important for the graft-versus-leukemia 
(GvL) effect together with NK cells [162]. The general prin-
ciples of GvL and GvHD are outlined in detail elsewhere 
[163].  
 Ruggeri et al. [162] have recently underlined the impor-
tance of KIR ligand mismatching, i.e. donor NK cell recog-
nition of “missing self” on recipient targets, essential for 
triggering NK cell alloreactions beneficially for haplotype-
mismatched transplantation outcome [162]. However, this is 
not supported by other studies [164, 165], and thus the effect 
of KIR ligand mismatching on the outcome of unrelated do-
nor transplantation for AML patients, still remains obscure. 
CONCLUDING REMARKS 
 Both the cellular innate and adaptive immune system in 
human AML patients differ from healthy individuals. AML 
patients are immunocompromized initially due to the disease 
and later due to intensive chemotherapy. We have included 
several examples of the importance of the immunological 
compartment and clinical significance in AML patients be-
fore, during and after treatment. However, future studies will 
be necessary to clarify the impact of the many immunologi-
cal conditions for clinical relevance. 
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